01.19.26 -- Europe In 2026: Resilience Through Uncertainty

Taking a molecule from drug substance to drug product often falters at the handoff. In this webinar, KBI Biopharma and Argonaut Manufacturing Services share how integrated CDMO-to-fill-finish partnerships eliminate silos, streamline quality, and reduce risk. Join a candid fireside chat on the top 10 quality challenges and proven solutions that cut timelines by 2–3 months from development through late-stage commercialization. Click here to learn more.

By working with a single supplier that can handle the entire manufacturing value chain, companies can reduce risk, improve flexibility, and accelerate their time to market.

Explore how Annex 1 applies to low bioburden DS manufacturing and promotes a risk-based approach to contamination control that balances regulatory compliance with operational efficiency.

With early, in-house viral clearance assessment, this solution empowers biopharma teams to optimize processes, cut expenses, and safeguard quality before GMP production begins.

The difference between QbD as burden and QbD as advantage lies in critical thinking supported by structure — a hierarchy of metrics, toolsets, and tailored platforms.

Uncover how Annex 1 applies to low bioburden DS manufacturing and promotes a risk-based approach to contamination control that balances regulatory compliance with operational efficiency.

Early collaboration and technical evaluation to select the right primary container materials prevent costly delays, ensuring specialized delivery systems reach patients efficiently and safely.

See real-world case studies showing how advanced characterization analytics and mass spectrometry resolve protein quality issues, prevent costly delays, and reduce risk across the lifecycle.

Orphan drug development is a journey marked by challenges at every step. From patient recruitment to aseptic fill finish, overcoming hurdles is critical for bringing life-saving treatments to market.

Next Generation Manufacturing (NGM) integrates advanced process design, digital innovation, and strategic facility planning to facilitate agile, efficient, and sustainable biopharmaceutical production.

This advanced cell line development technology overcomes production challenges related to the expression and scalability of complex biologics.

Discover analytical strategies designed to address challenges occurring during development of new molecular formats such as chain assembly, multiple-MoAs, and diverse post-translational modifications.

Standardized, continuously optimized facility design enables reliable biomanufacturing that improves quality, accelerates timelines, and ensures consistent performance across sites.

The journey of a novel bioconjugate into clinic is complex and uncertain. Explore the particular challenges when moving a bioconjugate candidate from early development into clinic.

Sterile fill-finish and device assembly capabilities span global sites, offering scalable solutions, analytical testing, and regulatory compliance for combination products and small-batch technical programs.

As a fully integrated CDMO, we offer a comprehensive suite of services, from early-stage research to robust commercial manufacturing, within our state-of-the-art facilities.

Accelerate your biopharma journey with a comprehensive service portfolio designed to speed development, reduce costs, and minimize risk from molecule to market.